Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM89WA1)

Drug Name

MBX-3254 Drug Info

Synonyms

GPR119 follow-on compounds (diabetes); GPR119 follow-on compounds (diabetes), Metabolex; MBX-2982 follow-on compounds (diabetes), Metabolex

Indication

Disease Entry	ICD 11	Status	REF
Non-insulin dependent diabetes	5A11	Investigative	[1]

Cross-matching ID

TTD Drug ID: DM89WA1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Glucose-dependent insulinotropic receptor (GPR119)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanfacine extended release	DMB1CZ8	Attention deficit hyperactivity disorder	6A05.Z	Approved	[1]
DS-8500	DMUXIRM	Diabetic complication	5A2Y	Phase 2	[2]
SAR-260093	DMBJU2G	Type-2 diabetes	5A11	Phase 2	[3]
GSK1292263	DMDMXKQ	Gastric adenocarcinoma	2B72	Phase 2	[4]
BMS-903452	DM7JW0B	Type-2 diabetes	5A11	Phase 1	[5]
APD-597	DM36FOG	Type-2 diabetes	5A11	Phase 1	[6]
DA-1241	DMPJA64	Type 2 diabetes	5A11	Phase 1	[7]
APD668	DMN8R2U	Type-2 diabetes	5A11	Discontinued in Phase 1	[8]
PSN821	DMGEWUS	Type-2 diabetes	5A11	Terminated	[9]
N-oleoylethanolamide	DMJQ4L7	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucose-dependent insulinotropic receptor (GPR119)	TT7QNVC	GP119_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
2	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
3	GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59.
4	Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.PLoS One.2014 Apr 3;9(4):e92494.
5	Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J MedChem. 2014 Sep 25;57(18):7499-508.
6	Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5.
7	ClinicalTrials.gov (NCT03646721) A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM. U.S. National Institutes of Health.
8	Announces Initiation of Phase 1 Clinical Trial of Arena Type 2 Diabetes Drug Candidate in Collaboration With Ortho-McNeil. Arena Pharmaceuticals, Inc. FEBRUARY 07, 2006.
9	Clinical pipeline report, company report or official report of Astellas Pharma (2011).
10	Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.